Structure Therapeutics Inc. (GPCR)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Structure Therapeutics: The Dark Horse Has Taken The Lead - But Is It Enough?
Structure Therapeutics Inc. has evolved from a “dark horse” to a leading contender in the oral GLP-1 obesity drug market. GPCR's market cap surged from $1.3B to $5B in five months, reflecting heightened investor confidence after a successful Phase II readout and improved competitive positioning. The weight-loss drug market has shifted to mass-market pricing, with cash options as low as $149/month, broadening patient access.
Structure CEO Ray Stevens talks its obesity drug portfolio
Ray Stevens, Structure CEO, joins 'Fast Money' to talk its weigh-loss drug pipeline, potential M&A, and more.
What Awaits These 4 Biotech Stocks That More Than Doubled in 2025
IONS, GPCR, MNPR and KOD more than double in 2025 as policy clarity, M&A revival and clinical wins lift biotech momentum into 2026.
GPCR Stock Soars 102% on Strong Phase II Obesity Data for Aleniglipron
Structure Therapeutics jumps after phase II data show aleniglipron delivering strong, durable weight-loss results across multiple studies.
Structure Therapeutics Inc. (GPCR) Discusses Topline Results from ACCESS Program of Oral Small Molecule GLP-1 Receptor Agonist Transcript
Structure Therapeutics Inc. (GPCR) Discusses Topline Results from ACCESS Program of Oral Small Molecule GLP-1 Receptor Agonist Transcript
Why Structure Therapeutics Stock Was Stumbling This Week
The past few days haven't been kind to most stocks in the white-hot obesity drugs space. One developer of a weight loss medication, clinical-stage biotech Structure Therapeutics (GPCR 0.16%), was a victim of a general rout in the segment.
Septerna Poised For Biopharma Breakthrough: Analysts Cite GPCR Innovation And 2025 Milestones
A couple of analysts initiated coverage on Septerna, Inc. SEPN, which debuted on NASDAQ last month.
Best Momentum Stocks to Buy for October 23rd
GPCR, RUSHA and NTRA made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 23, 2024.
Does Structure Therapeutics Inc. Sponsored ADR (GPCR) Have the Potential to Rally 115.8% as Wall Street Analysts Expect?
The consensus price target hints at an 115.8% upside potential for Structure Therapeutics Inc. Sponsored ADR (GPCR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
What's in Store for Structure Therapeutics (GPCR) in Q2 Earnings?
Structure Therapeutics (GPCR) is expected to provide updates on the developmental pathway of its lead product candidate, GSBR-1290, for diabetes and obesity indications in the Q2 earnings release.
The 3 Most Undervalued Biotech Stocks to Buy in July 2024
There's always a strong case for undervalued biotech stocks. For one, the industry is only expected to grow.
Could Structure Therapeutics Become the Next Novo Nordisk?
Structure Therapeutics is developing a potentially powerful weight loss medicine. That medicine may end up being more effective than Novo Nordisk's offerings.
